Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
55
resultados
Última actualización
03/05/2025 [07:40:00]
Resultados 25 a 50 de 55
Resumen de: JP2024037794A
To provide a method for measuring an amount of singly or multiply phosphorylated p217+tau protein in a sample, regarding compositions and methods for detecting neurodegeneration.SOLUTION: A method for measuring a p217+ tau peptide in a sample, comprises: (i) contacting the sample with a capture antibody against a p217+ tau epitope to capture the p217+ tau peptide in the sample; and (ii) contacting the captured p217+ tau peptide with at least one of a first detection antibody against an epitope comprising amino acid residues 119 to 126 of a tau protein and a second detection antibody against an epitope comprising amino acid residues 7 to 20 of the tau protein, and measuring at least one of an amount of the p217+ tau peptide and an amount of a long p217+ tau peptide, where amino acid numbering refers to a specific amino acid sequence.SELECTED DRAWING: None
Resumen de: US2025101491A1
Method for diagnosing Alzheimer's disease in an individual, comprising the steps of providing at least one serum sample derived from the individual, providing at least one preparation of phage clones expressing peptides that mimic conformational epitopes of the Aβ-42 peptide, reacting said at least one serum sample with said at least one preparation of phage clones expressing peptides that mimic conformational epitopes of Aβ-42, so that antibodies that may be present in said serum and are directed against the Aβ-42 peptide bind to the peptides expressed by phage clones of said preparation of phage clones, detecting, by real-time PCR technique, the quantity of phage clones of said preparation to which said antibodies have bound, and determining, based on the quantity of phage clones of said preparation to which said antibodies have bound, whether the individual from whom said serum sample was derived suffers from Alzheimer's disease.
Resumen de: AU2023329330A1
Provided herein are antibodies, or fragments thereof, that specifically bind to a microtubule-binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting species of MTBR in blood or cerebral spinal fluid, and the use of such detection for diagnosing, prognosing, or staging pathological features and/or clinical symptoms of tauopathies, and to choose treatments appropriate for a given disease stage.
Resumen de: WO2025064229A1
The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and/or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.
Resumen de: US2025101018A1
Described herein are compounds of formula (I), and pharmaceutically acceptable salts, solvates, hydrates, isotopically labeled derivatives and radiolabeled derivative thereof, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for detecting and imaging Tau aggregates in the brain for detection of Alzheimer's disease (AD) in a subject.
Resumen de: EP4527944A1
The present invention relates to a Gram-positive, anaerobic and non-spore-forming bacterium in the stool that can serve as a biomarker for diagnosing, assessing and predicting the development of dementia related diseases induced by high fat diet consumption. This was done by analyzing bacterial metagenome using cecum samples derived from AD mice models and to investigate the increase of a specific bacterium's relative abundance and its association with the disease. By using the strategy in this invention, it is possible to diagnose and predict AD at an early stage, so that it is possible to delay the onset of the disease or to prevent the onset of the disease through proper management thereby lowering the incidence of AD and improving the therapeutic effect.
Resumen de: EP4528281A2
The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.
Resumen de: EP4528274A2
The invention relates to the use of biomarkers of TrkB-FL, TrkB-ICD, TrkB-T', the TrkB-T':TrkB-FL ratio, or the TrkB-ICD:TrkB-FL ratio in the in vitro diagnosis of Alzheimer Disease (AD) or for determining the stage of AD, methods for their use, methods of diagnosis, methods of monitoring disease progression, in neuropathological diseases, in particular for Alzheimer's disease.
Resumen de: AU2023329158A1
The invention relates to methods of detecting, diagnosing or monitoring an inflammatory condition of the central nervous system, in particular by detecting or measuring neutrophil extracellular traps, extracellular traps and/or cell free nucleosomes.
Resumen de: AU2023334129A1
The invention relates to identification of an intron-retaining Tau splicing isoform as a novel Alzheimer's disease biomarker. Provided herein are polypeptides to generate binding molecules, such as antibodies specific for the Tau11i isoform, oligonucleotides and antibodies for use in methods for detecting the Tau11i isoform in a sample and methods for use in diagnosis for Alzheimer's disease.
Resumen de: WO2025058089A1
The purpose of the present invention is to provide an agent for suppressing amyloid β aggregation/deposition and an agent for suppressing/improving cognitive decline of a subject both of which are expected to have the effect of treating and/or preventing Alzheimer's disease. Specifically, the present invention pertains to an agent for suppressing amyloid β aggregation/deposition or an agent for suppressing/improving cognitive decline of a subject, the agent comprising an extract of a plant belonging to Myrtaceae.
Resumen de: US2025092361A1
A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.
Resumen de: US2025093343A1
The invention provides assays and methods for characterization of specific extracellular vesicle (EV) populations, and to the preparation of improved EV compositions for therapy and diagnosis. Specifically, the invention in embodiments thereof provides methods and kits for analyzing blood-derived samples, as well as to the production and use of tissue-derived circulating EV populations characterized by unexpectedly small dimensions and advantageous properties.
Resumen de: WO2025057945A1
The present application includes: a method for determining whether a patient has cerebral amyloid angiopathy, the method comprising measuring the expression level of α1-acid glycoprotein in a sample collected from the patient; a method for determining the presence or the risk of side effects of a therapy using an anti-amyloid β antibody against Alzheimer's disease, the method comprising measuring the expression level of α1-acid glycoprotein in a sample collected from a patient; and a method for selecting a patient for a therapy using an anti-amyloid β antibody against Alzheimer's disease, the method comprising measuring the expression level of α1-acid glycoprotein in a sample collected from the patient; and the like.
Resumen de: AU2023264886A1
The present disclosure provides devices for the detection and/or quantification of neurotoxic amyloid-type protein aggregates, comprising a doxycycline derivative immobilized on an appropriate surface, as well as electrochemical and immunochemical methods associated to the use of such devices.
Resumen de: US2023160912A1
Disclosed are an immunoassay method capable of highly sensitively measuring amyloid β in a blood sample, and a kit therefor. The immunoassay method for amyloid β is a method of immunoassay of amyloid β in a blood sample, wherein the immunoassay is carried out in the presence of an anionic polymer such as a dextran sulfate salt or a polystyrene sulfonic acid salt. The kit for immunoassay of amyloid β in a blood sample comprises: an anti-amyloid β antibody or an antigen-binding fragment thereof; and an anionic polymer.
Resumen de: KR20250037394A
본 명세서에는 알츠하이머 환자에 특이적인 B 세포 수용체 클론형을 검출하는 제제를 포함하는 알츠하이머 예측 또는 진단용 조성물, 시스템 및 정보제공방법에 관한 것으로, 본 발명의 일 측면에 따른 조성물은 알츠하이머 환자에 특이적인 B 세포 수용체 (B cell receptor, BCR) 클론형을 검출하는 제제를 포함함으로써 방사성 물질을 사용하는 MRI와 PET 스캔의 방법 외에 병리적 특징의 발현이나 축적에 관계없이 비침습적이고 편리한 방식으로 단순히 피험자로부터 분리한 말초혈 단핵구를 이용하여 알츠하이머를 예측 또는 진단할 수 있는 우수한 효과가 있다.
Resumen de: AU2023347307A1
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: US2025084157A1
The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.
Resumen de: WO2025050415A1
Disclosed in the present invention is the use of peripheral blood macrophages in the preparation of a reagent and/or a drug for the diagnosis, prognosis and treatment of Alzheimer's disease (AD). The present invention will open new doors for a better understanding of the disease mechanisms of Alzheimer's disease and may guide development in new directions for early diagnosis, prognosis and treatment, so as to enable early prevention and treatment of Alzheimer's disease.
Resumen de: WO2025054610A1
Dementia is a brain disease which results in irreversible and progressive loss of cognition and motor activity. Despite global efforts, there are no simple and reliable diagnosis or treatment options. Embodiments of the disclosed technology provide an aptamer-based graphene field-effect transistor (GFET) biosensor platform that has high sensitivity and precision across a range of epidemiologically significant Alzheimer's disease and Parkinson's disease variants, and enables at-home and point-of-care (POC) testing for neurodegenerative diseases. An example method of detecting for detecting a molecular biomarker for dementia of a subject includes receiving a biological sample comprising the molecular biomarker for dementia, contacting the biological sample with a biosensor device comprising a GFET-based detection chip, and detecting a presence of the molecular biomarker for dementia in the biological sample.
Resumen de: AU2023264886A1
The present disclosure provides devices for the detection and/or quantification of neurotoxic amyloid-type protein aggregates, comprising a doxycycline derivative immobilized on an appropriate surface, as well as electrochemical and immunochemical methods associated to the use of such devices.
Resumen de: WO2023214324A1
The present invention relates to a method for diagnosing neurodegenerative diseases, wherein said method comprises measuring the JNK3 levels in a biological sample selected from plasma, CSF, and saliva. In an embodiment, said method also comprises measuring P-JNK3.
Resumen de: US2025064417A1
Disclosed are methods for using regional tau PET scans for identifying a subject having or suspected of having, diagnosing, and treating Alzheimer's disease. The methods are particularly useful for treating and diagnosing a patient as susceptible and at risk for developing amyloid-beta and cognitive dysfunction using tau-PET imaging based on regional tau PET measures.
Nº publicación: JP2025506389A 11/03/2025
Solicitante:
エーザイ・アール・アンド・ディー・マネジメント株式会社
Resumen de: MX2024009492A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
BOPI
Sede Electrónica
